This gamma scintigraphy imaging study was the first to assess pulmonary and extrathoracic deposition and regional lung deposition patterns of a radiolabelled long-acting muscarinic antagonist/long-acting β 2 -agonist fixed-dose combination glycopyrronium/formoterol fumarate dihydrate (GFF) 14.4/10 μg (equivalent to glycopyrrolate/formoterol fumarate 18/9.6 μg), delivered by pressurized metered dose inhaler (pMDI) using novel co-suspension delivery technology. In this Phase I, randomized, single-centre, single-blind, single-dose, twotreatment, crossover, placebo-controlled study (PT003020), 10 healthy male adults received two actuations of GFF pMDI (7.2/5.0 μg per actuation) and placebo pMDI (containing phospholipid-based porous particles without active pharmaceutical ingredient), both radiolabelled with 99m Tc, up to 5 MBq per actuation. Gamma scintigraphy images of lungs, stomach, head and neck were recorded. In addition, images of the actuators after use, collected mouth washings and exhalation filters were acquired. On average, 38.4% of the emitted dose of radiolabelled GFF pMDI, and 32.8% of radiolabelled placebo pMDI, was deposited in the lungs. The percentage emitted dose detected in the oropharyngeal and stomach regions was 61.4% and 66.9% for radiolabelled GFF pMDI and placebo pMDI, respectively. For both treatments, ≤0.25% of the emitted dose was detected in the exhalation filter. The normalized outer/inner ratio was 0.57 and 0.59 for radiolabelled GFF pMDI and placebo pMDI, respectively, and the standardized central/peripheral ratio was 1.85 and 1.94 respectively, indicating delivery of both co-suspension delivery technology formulations throughout the airways. There were no new or unexpected safety findings. In conclusion, both formulations were efficiently and uniformly deposited in the lungs with similar regional deposition patterns, oropharyngeal and stomach deposition, exhalation fraction and actuator-recovered dose. http://dx.
Introduction
Inhaled bronchodilators are the key treatment in the symptom management of stable chronic obstructive pulmonary disease (COPD) (Global Initiative for Chronic Obstructive Lung Disease, 2017) . Several studies have reported that patients treated with a long-acting muscarinic antagonist and a long-acting β 2 -agonist (LAMA/LABA) fixed dose combination (FDC) show clinical improvements over those receiving an individual monocomponent (Bateman et al., 2013; Celli et al., 2014; Rabe et al., 2015) . Hence, a combination of a LAMA and a LABA is recommended for those patients whose symptoms are not relieved by a single bronchodilator (Global Initiative for Chronic Obstructive Lung Disease, 2017) . Combination therapy in the management of COPD can be delivered using multiple inhaler devices. However treatment adherence is improved with a FDC in a single inhaler compared to multiple devices (Yu et al., 2011a; Yu et al., 2011b) .
Glycopyrronium/formoterol fumarate dihydrate (GFF) 14.4/10 μg (equivalent to glycopyrrolate/formoterol fumarate 18/9.6 μg) is a LAMA/LABA FDC delivered by pressurized metered dose inhaler (pMDI) using novel co-suspension delivery technology. The co-suspension delivery technology utilises a strong non-specific association between micronized drug crystals and phospholipid-based porous particles when they are suspended together in the pMDI propellant hydrofluoroalkane (HFA) 134a (1,1,1,2-tetrafluoroethane), resulting in uniform suspensions and consistent dose delivery (Vehring et al., 2010; Vehring et al., 2012) . GFF pMDI has demonstrated improvements in lung function parameters in patients with moderate-to-very severe COPD in Phase III clinical trials (Hanania et al., 2017; Martinez et al., 2017) .
Gamma scintigraphy is an established method for quantifying the total deposition of inhaled drugs in the lungs, as well as the extrathoracic deposition in the oropharyngeal and stomach regions (Chrystyn, 2000; Darquenne et al., 2016; Newman et al., 2012) . In addition, gamma scintigraphy can be used to evaluate regional lung deposition, i.e., outer versus inner lung deposition (Biddiscombe et al., 2011; Darquenne et al., 2016; Newman et al., 2012) . For the effectiveness of inhaled drugs, both total lung deposition and deposition pattern are important. As the small airways are the major site of airflow obstruction in COPD, a lack of delivery to the distal airways could contribute to poor disease control in patients with COPD (Usmani, 2012) . Targeting inhaled drugs to the distal airways may be achieved by increased fine particle fraction, small drug particle size, or slow aerosol velocity (Usmani, 2012) .
Previous gamma scintigraphy studies have investigated lung deposition patterns of single drugs (Boyd et al., 2004; Hirst et al., 2002; Leach et al., 2016; Newman et al., 2006; Nikander et al., 2010; Usmani et al., 2005; Warren et al., 2002; Weers et al., 2009) . However, few studies have assessed the lung deposition of FDCs (Brand et al., 2008; de Backer et al., 2010) , and no scintigraphic study assessing the lung deposition of LAMA/LABA FDCs intended for the long-term maintenance therapy for patients with COPD has been reported.
Here, we present the results of a Phase I, randomized, placebocontrolled clinical study (PT003020), which used gamma scintigraphy imaging to assess the pulmonary deposition of aerosols from radiolabelled GFF pMDIcontaining the co-suspension delivery technology based formulation of glycopyrronium and formoterol fumarate drug crystals with phospholipid porous particlesand the corresponding radiolabelled placebo pMDI (phospholipid porous particles-only suspension) in healthy subjects (primary objective). The regional deposition patterns in the lung, the proportion of drug deposited in extrathoracic areas and the proportion of drug that was exhaled were also evaluated (secondary objectives).
Materials and methods

Study design
This study was a randomized, single-blind, two-treatment, crossover, single-dose, single-centre, placebo-controlled gamma scintigraphy imaging study in 10 healthy male adults ( Fig. 1 ). Subjects attended a screening visit within 28 days of the first treatment period, which included lung function and clinical laboratory tests, medical history, vital signs, 12-lead electrocardiogram (ECG) and a physical examination.
Eligible subjects were randomized to one of two treatment sequences. Each of the two treatment periods was approximately 2 days long (from the day before dosing until 24 hour post-dose), with a minimum washout period of 5 days (7 ± 2 days). A post-study followup was conducted 7-14 days after the last dose.
Prior to the first dosing (Day −1; treatment period 1), a 81m Kr gas ventilation scan was performed to define the ventilated area of the lungs for each subject. In addition, 57 Co transmission scans of the thorax and abdomen, and the head and neck were conducted on Day 1 of treatment period 1 to evaluate the regional tissue attenuation of deposited radioactivity.
The study was designed in accordance with the International Society of Aerosols in Medicine (Regulatory Affairs Networking Group for the Standardization of Lung Imaging Techniques) recommendations for standardizing scintigraphy studies and for the assessment of regional lung deposition . The study was also conducted in accordance with Good Clinical Practice guidelines including the International Council on Harmonization, the US Code of Federal Regulations and the Declaration of Helsinki. Written informed consent was obtained from each subject prior to performing any screening evaluations and entry into the study. Approval for administration of radioisotopes was obtained from the Administration of Radioactive Substances Advisory Committee, Department of Health, UK.
Radiolabelling and validation
The suspended particles were radiolabelled, on each study day, by adding a fixed amount of technetium-99m-pertechnetate ( 99m Tc) to each canister, a method adapted from Hirst et al. (2002) . The 99m Tc label was associated with the formulation particles so that after actuationas the propellant evaporated awaythe aerodynamic particle size distribution of the radiolabel would be the same as that of the aerosolized formulation particles. This was determined by Next Generation Impactor™ (NGI) prior to the clinical arm of this study as part of an in vitro validation study, carried out according to previously published guidance . Aerodynamic particle size distribution by NGI and delivered dose of the radiolabelled pMDIs were confirmed both immediately before and after dosing in each arm of the study.
Subjects
Healthy male subjects, 28-50 years of age, with a body weight of ≥ 50 kg and a body mass index of 19-30 kg/m 2 at screening, who had test results in the normal range for complete blood count, serum creatinine, electrolytes, serum glucose, aspartate aminotransferase/alanine aminotransferase and total bilirubin were eligible for participation in the study.
The main exclusion criteria were: a forced expiratory volume in 1 s (FEV 1 ) < 80% of predicted value and/or a FEV 1 /forced vital capacity (FVC) ratio < 0.7 at the screening visit; an inability to demonstrate competent use of the pMDI device (including sufficient inspiratory flow rate) or use of exhalation filter after training; or any abnormal findings on the 81m Kr ventilation scan. Other exclusion criteria were clinically significant illnesses that may have interfered with participation in this study; previous participation in any study of GFF pMDI conducted or sponsored by Pearl Therapeutics, Inc.; or abnormal findings in a previous chest X-ray or computerized tomography scan.
Inhaler training
Trained staff instructed the subjects on the use of pMDIs using the Vitalograph® Aerosol Inhalation Monitor™ (AIM™), a commercially available pMDI training simulator which uses a red/green traffic light system to indicate correct co-ordination of actuation and inhalation, flow rate and breath-hold. Subjects were trained, with a pMDI containing only HFA 134a propellant, to ensure a good seal on the actuator, to actuate the pMDI correctly, to inhale at an appropriate flow rate (in the region of 30-90 L/min), and to perform a breath hold of 10 s followed by exhalation into a low resistance filter. Training took place at screening, on inclusion into each treatment period, and in the 10 minute interval immediately prior to dosing. Furthermore, site staff retrained subjects until they demonstrated correct use of the pMDI.
Treatment
Under the supervision of the investigator, each subject received GFF pMDI 14.4/10 μg (two inhalations of 7.2/5.0 μg, radiolabelled with 99m Tc, up to 5 MBq per actuation) and placebo pMDI (two inhalations, radiolabelled with 99m Tc, up to 5 MBq per actuation) in a randomized, balanced, crossover design. The total amount of radioactivity used in this study was 7-8 MBq per dose (i.e., 2 actuations). Immediately after each inhalation, subjects performed a 10-second breath hold and exhaled into an exhalation filter. After the second breath hold and exhalation, subjects rinsed their mouth with approximately 20 mL of water; expelled washings were collected. To minimize interference from any radiolabel present in the oesophagus, subjects then swallowed approximately a quarter of a slice bread and 100 mL water prior to gamma scintigraphy imaging.
Outcome variables
The primary outcome variable was the percentage of the total emitted radioactive label dose deposited in the lungs for GFF pMDI and placebo pMDI. Secondary outcome variables included the percentage of the total emitted radioactive label dose of GFF pMDI and placebo pMDI deposited in the oropharyngeal and stomach regions, in the exhalation filter, and the fraction left behind in the actuator (expressed as a percentage of the ex-valve dose), as well as the regional airway deposition ratios (normalized outer/inner [nO/I] ratio [as per the methods in Newman et al. (2012) ] and standardized central/peripheral [sC/P] ratio [as per Biddiscombe et al. (2011) ]. Additional endpoints included lung function assessments (FEV 1 and FVC) and safety endpoints (i.e., adverse events [AEs], clinical laboratory testing, vital signs, 12-lead ECG and physical examination).
Assessments
At baseline, the ventilated area of the lungs for each individual subject was assessed by 81m Kr ventilation scan. Anterior and posterior views were acquired while the subject inhaled the 81m Kr gas until a reading of 200,000 counts was reached.
Gamma scintigraphy images were recorded immediately following completion of the dosing procedure, including posterior and anterior views of lungs and stomach, and lateral views of the head and neck. Each image was a maximum of 200 s in duration. Images of subject specific actuators, mouth washings and exhalation filters, were also acquired.
Lung function assessments were carried out at the screening visit and then 1 hour post-dosing in both treatment periods. Safety assessments were performed throughout.
Statistics
No formal sample size calculation was performed. However, 10 subjects were enrolled to ensure that at least 8 completed the study to allow a direct estimate of lung deposition to be made. All gamma scintigraphy imaging data analyses were based on the safety and perprotocol populations. All demographic and baseline characteristic analyses and safety analyses were based on the safety population.
The emitted dose was defined as the sum of radioactivity (corrected, as appropriate, for background radioactivity, tissue attenuation, image duration and radioactive decay) detected in the lungs and oropharynx (including mouth washings and stomach deposition) and on the exhalation filter. The corrected counts in each area were expressed as a percentage of the emitted dose.
Total lung deposition for each subject was calculated using lung margins, defined by drawing a region of interest (ROI) around the geometric mean lung image calculated from anterior and posterior 81m Kr ventilation images. The individual ventilation ROIs were superimposed over each lung image (i.e., anterior and posterior) acquired for each subject following drug treatment. The radioactivity within each of the defined ROIs was calculated. Oropharyngeal and stomach deposition were determined from regions defining the oropharynx and stomach drawn on the anterior and posterior images. Radioactive counts determined in the anterior and posterior views were used to calculate geometric mean counts for each region of interest.
Actuator deposition was determined using the image from the vessel containing the actuator washings following its removal from the pMDI canister. The counts in this image were expressed as a percentage of the total ex-valve dose, i.e., emitted dose plus actuator counts, after correction for background activity, image duration and radioisotope decay.
The regional airway deposition ratios, O/I ) and C/P (Biddiscombe et al., 2011) , of radiolabelled GFF pMDI and placebo pMDI in the lungs were determined after correcting for regional lung volume (using O/I and C/P from the 81m Kr gas scan) to generate normalized O/I (nO/I) and standardized C/P (sC/P). These were calculated for the geometric mean image of the right lung only, since activity associated with the stomach may interfere with the left lung image. The nO/I and sC/P ratios were calculated by analyzing the relative proportions of radiolabelled formulation within two compartments. For nO/I ratio, the outer region rectangle was defined by the margin of the whole-lung in the 81m Kr image (Fig. 2) . The inner region rectangle was equal to half the width and half the height of the whole lung rectangle, positioned on the interior boundary of the lung, centred by height. The inner region is equal to 25% of the whole lung rectangle . The C/P ratio was calculated according to method B in Newman et al. (2012) .
Primary and secondary output variables were subjected to a mixed effects analysis of variance (ANOVA) including fixed effects for treatment, study period and sequence of administration, and a random effect of subject nested within sequence. Point estimates and 95% confidence intervals (CI) for the differences between the two treatments were constructed using the residual mean square error obtained from the ANOVA.
Start of study
Results
Radiolabelling validation
The NGI analytical tests conducted during radiolabelling method development demonstrated that the aerodynamic size distribution of the emitted aerosol particles for each of the analytes, i.e. glycopyrronium and formoterol fumarate dihydrate, were comparable to those from the nonradiolabelled canisters, confirming that the radiolabelling process did not alter the formulation. As an example, the deposition patterns of glycopyrronium are presented in Fig. 3 . The effective cut-off diameter (μm) for each stage is shown for a flow rate of 30 L per minute, as is the Pharmacopoeial standard (United States Pharmacopeial Convention, 2017). The mass median aerodynamic diameter (MMAD) for glycopyrronium ranged from 2.98 to 3.05 μm with the geometric standard deviation ranging from 1.605 to 1.614 μm. Tests immediately prior to radiolabelled aerosol administration on each dosing day also confirmed that each radiolabelled canister delivered the correct amount of radioactivity. Validation of the radiolabelling process confirmed that the radiolabelled aerosols fulfilled criteria described by ) (data not shown).
Subjects
Of the 30 subjects screened, 19 did not meet the selection criteria and one did not attend Day 1 (details of subjects who failed the selection criteria can be found in the Supplementary material). Ten subjects were randomized and completed the study. There were no major protocol deviations. Lung function data and 81m Kr gas scans from all subjects were considered normal. Demographic characteristics are summarized in Table 1 .
Deposition
Emitted dose
The mean (standard deviation [SD]) percentage of the metered dose detected in the actuator after inhalation was 10.1% (1.6) for radiolabelled GFF pMDI and 8.9% (1.5) for radiolabelled placebo pMDI. This reflects the percentage of the metered dose that did not leave the device; the remaining percentage was considered the emitted (delivered) dose.
Primary outcome variable
The mean (SD) percentage of the emitted dose of radiolabelled GFF pMDI deposited in the lungs was 38.4% (10.0), and that of radiolabelled placebo pMDI was 32.8% (10.2) ( Table 2 ). The least squares mean difference in the percentage of the emitted dose delivered to the lung between radiolabelled GFF pMDI and radiolabelled placebo pMDI was 5.6% (95% CI −1.4, 12.6). Fig. 4 shows the reflected posterior gamma scintigraphy images for the 81m Kr ventilation, placebo pMDI and GFF pMDI of two subjects who had deposition fractions closest to the mean deposition of the study population.
Secondary outcome variables
The mean (SD) percentage of the emitted dose deposited in both the oropharyngeal and stomach regions was 61.4% (9.8) for radiolabelled GFF pMDI and 66.9% (10.1) for radiolabelled placebo pMDI (Table 2) . Of the dose deposited in the oropharyngeal and stomach regions, 7.4% or less was deposited in the oropharynx. A very low percentage (≤ 0.25%) of the emitted dose was detected in the exhalation filter for radiolabelled GFF pMDI and for radiolabelled placebo pMDI ( Table 2) .
The mean (SD) nO/I regional airway deposition ratio was 0.57 (0.13) for radiolabelled GFF pMDI and 0.59 (0.17) for radiolabelled placebo pMDI. The mean (SD) sC/P regional airway deposition ratio was 1.85 (0.72) for radiolabelled GFF pMDI and 1.94 (1.15) for radiolabelled placebo pMDI (Table 2) .
Lung function
As expected in this healthy study population, there were no clinically significant differences in lung function parameters between radiolabelled GFF pMDI-and placebo pMDI-treated subjects at 1 h postdose (data not shown).
Safety and tolerability
Four subjects reported seven AEs during the study, including one subject who reported two AEs prior to dosing. All AEs were mild or moderate in severity, with only one being considered to be probably related to the study medication (blurred vision, radiolabelled GFF pMDI arm). The most common treatment-emergent AE (TEAE) was headache, which was reported by two subjects (one mild, one moderate; both radiolabelled placebo pMDI arm). There were no severe TEAEs, serious TEAEs, withdrawals due to TEAEs or deaths during the study (Table 3 ). In addition, there were no clinically significant findings in the clinical laboratory, vital sign and 12-lead ECG assessments, or the physical examinations.
Discussion
The radiolabelled glycopyrronium/formoterol fumarate combination GFF pMDI and the placebo pMDI formulations, both delivered using novel co-suspension delivery technology, were deposited in the lungs with similar deposition fraction and regional deposition patterns, as assessed by total lung deposition and nO/I and sC/P regional lung deposition ratios. Of the emitted GFF pMDI dose, a total of 38.4% was deposited in the lungs, with a nO/I regional deposition ratio of 0.57. The similar in vivo deposition patterns of GFF pMDI and placebo pMDI were consistent with their similar in vitro aerodynamic particle size distributions.
The combined oropharyngeal and stomach deposition of radiolabelled GFF pMDI and placebo pMDI were also similar, as were the individual regions, with most of the radiolabel recovered in the mouthwash or detected in the stomach. The exhaled fraction of radiolabelled GFF pMDI and placebo pMDI was very low (≤0.25% for both).
It is important to target inhaled drugs to small airways deep in the lung, as the small airways display pathological, physiological and structural abnormalities in patients with COPD (Usmani, 2012; Usmani and Barnes, 2012) . The in vitro aerodynamic particle size distribution of GFF pMDI and placebo pMDIs indicated that both aerosols have coarse, medium-sized particles suitable for proximal and central deposition, as well as extra-fine particles for deep penetration. The nO/I ratios of 0.57 (GFF pMDI) and 0.59 (placebo pMDI) confirmed that the aerosol particles of GFF pMDI and placebo pMDI delivered using cosuspension delivery technology reached both the outer and the inner lung regions in vivo.
Previous gamma scintigraphy studies of inhaled therapies have been conducted in healthy subjects, patients with asthma, and patients with COPD, and have evaluated inhaled corticosteroids (ICS), short-acting β 2 -agonist (SABA) monotherapies, and combination therapies such as short-acting muscarinic antagonist/SABA and LABA/ICS (Boyd et al., 2004; Brand et al., 2008; de Backer et al., 2010; Hirst et al., 2002; Leach et al., 2016; Newman et al., 2006; Nikander et al., 2010; Usmani et al., 2005; Weers et al., 2009) . Our study in healthy subjects was the first to evaluate a LAMA/LABA FDC, which is an important maintenance treatment for patients with COPD (Global Initiative for Chronic Obstructive Lung Disease, 2017).
When comparing the current results with those from other high efficiency inhaler systems, including HFA pMDI, the overall lung fractions of radiolabelled GFF pMDI and placebo pMDI were broadly similar to or higher than those observed from other HFA suspension pMDIs (21-34% lung deposition) (Brand et al., 2008; de Backer et al., 2010; Hirst et al., 2002; Leach et al., 2016) . A recent study reported a lung deposition of 55% for a beclomethasone solution HFA pMDI with a small particle size (MMAD 0.7 μm) characteristic of solution formulations (Leach et al., Fig. 3 . Glycopyrronium aerodynamic particle size distribution from GFF pMDIs. Comparison of glycopyrronium aerodynamic particle size distribution from non-radiolabelled GFF pMDIs, during radiolabelling validation, and from radiolabelled GFF pMDIs used in this study. The effective cut-off particle size for each stage is shown for an inhalation flow rate of 30 L per minute. Similar results were obtained for formoterol fumarate from GFF pMDIs and placebo pMDI (data not shown). Abbreviations: GFF = glycopyrronium/formoterol fumarate dihydrate; FPD = fine particle dose; FPF = fine particle fraction; GP = glycopyrronium; GSD = geometric standard deviation; IP = induction port; MMAD = mass median aerodynamic diameter; MOC = micro-orifice collector; pMDI = pressurized metered dose inhaler; SD = standard deviation. G. Taylor et al. European Journal of Pharmaceutical Sciences 111 (2018 ) 450-457 2016 . When compared with a comprehensive collection of scintigraphy results (Clark, 2012) , the GFF and placebo pMDIs lung deposition observed in the present study were higher than most traditional suspension pMDIs. However, a similar comparison of the regional deposition patterns is not feasible as the deposition parameters may not have been measured in the same way, some parameters may have been expressed differently, and unlike in this study, data may not have been normalized to lung volume or collected in accordance with the published standardization guidelines Newman et al., 2012) . The sample size and the enrolment of healthy subjects were similar to other gamma scintigraphy studies (Boyd et al., 2004; de Backer et al., 2010; Hirst et al., 2002; Nikander et al., 2010; Weers et al., 2009 ). The study was planned with healthy subjects to focus on the magnitude of the deposition and differences in the deposition patterns of the radiolabelled GFF pMDI and placebo pMDI formulations. The deposition Gamma scintigraphy images of the lung deposition of placebo pMDI and GFF pMDI are shown for two representative subjects, i.e. the subjects with deposition fractions closest to the mean of the study population. Abbreviations: GFF = glycopyrronium/formoterol fumarate dihydrate; pMDI = pressurized metered dose inhaler. magnitude of GFF pMDI and placebo pMDI, but perhaps not their deposition pattern, can be expected to be the same in patients, based on a study with a HFA pMDI in healthy subjects and patients with COPD and asthma (de Backer et al., 2010) . In this study, the overall lung deposition from a HFA pMDI was similar, regardless of the pathophysiological condition, albeit there was a moderate impact of the increased airway obstruction in patients with asthma or COPD on the regional deposition pattern. Additionally, while it is recognised that lung deposition of aerosols emitted from a pMDI may be influenced by inhaled flow and volume (Farr et al., 1995) , the intention in this study was to ensure that subjects were highly competent in their pMDI inhaler technique, using a commercially available training device (Vitalograph AIM), rather than constraining them to a specific written inhalation manoeuvre. As a result, the deposition values reported here should mirror those which may be achieved by patients who have received similar training in a clinical setting.
In conclusion, radiolabelled GFF pMDI and placebo pMDI, delivered via co-suspension delivery technology, were deposited in the lungs with similarly high efficiency and low exhaled fraction. The regional deposition patterns showed coverage of all regions of the lungs, consistent with the broad aerodynamic particle size distribution of the porous particles, and demonstrating that GFF pMDI has the potential to target drugs to both the proximal and the distal lung regions of patients.
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